Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06373835
Other study ID # EMODEPSIDE_LAOS
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 20, 2024
Est. completion date July 31, 2024

Study information

Verified date April 2024
Source Swiss Tropical & Public Health Institute
Contact Jennifer Keiser, PhD
Phone +41 61 284 81 11
Email jennifer.keiser@swisstph.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Efficacy, safety and pharmacokinetics of ascending dosages of emodepside and in comparison to ivermectin against Strongyloidiasis stercoralis in adults: randomized stage II seamless adaptive controlled trials


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date July 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Written informed consent signed by the participant him/herself - Males and females of age 18 or older - Infected with S. stercoralis (positive by at least two Baermann assays on two different days and infection intensities of at least 0.75 LPG in the two stool samples. - Agree to comply with the study procedures, including to be examined by a study physician at the beginning of the study and to provide three stool samples during the screening period (within a maximum of 10 days) and approximately three weeks after treatment (follow-up). - Female participants of childbearing potential to ensure adequate contraception during the study period. Exclusion Criteria: - No written informed consent by individual. - Presence of acute or uncontrolled systemic illnesses (e.g. severe anemia, clinical malaria) as assessed by a medical doctor, upon initial clinical assessment. - Recent history of acute or severe chronic disease, as assessed by a medical doctor or reported by the participant: Type 1 and/or 2 diabetes; Psychiatric disorders; Chronic heart, liver, or renal disease - Prior treatment with anthelmintics (eg, diethylcarbamazine [DEC], suramin, ivermectin, mebendazole or albendazole) within 4 weeks before planned study drug administration. - Actively participating in other clinical trials during the study. - Positive pregnancy test or breastfeeding women and planning to become pregnant within three months of study drug administration. - Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin within 4 weeks before planned study drug administration. - Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir. - Known allergy to study drugs or any of the ingredients

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Emodepside
5 mg tablets of emodepside and matching placebo tablets, 3mg ivermectin

Locations

Country Name City State
Lao People's Democratic Republic Lao Tropical and Public Health Institute Vientiane

Sponsors (2)

Lead Sponsor Collaborator
Swiss Tropical & Public Health Institute National Institute of Public Health, Vientiane, Laos

Country where clinical trial is conducted

Lao People's Democratic Republic, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cure rate (CR) of emodepside against Strongyloides stercoralis The CR will be calculated as the proportion of Strongyloides stercoralis larvae-positive participants at baseline who become larvae-negative after treatment. In the week between 14 and 21 days post-treatment
Secondary Safety and tolerability of the dose-dependent emodepside treatment regimes, and compared with ivermectin. AEs will be evaluated descriptively as the difference of proportion reported AEs before and after treatment. Actively evaluated at 3 hours, 24 hours, 72 hours, and 14 days post-treatment
Secondary Geometric Mean Larvae Reduction Rate (LRR) of emodepside against Strongyloides stercoralis. The LRRs will be calculated based on the geometric mean In the week between 14 and 21 days post-treatment
Secondary Exposure response of emodepside in adults Emodepside will be quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Drug concentrations will be calculated by interpolation from a calibration curve with a foreseen limit of quantification of approximately 1-5 ng/ml. Actively collected at 0 hours, 0.5 hours, 2.5 hours, 5 hours, 24 hours, 72 hours, and 14 days post-treatment
Secondary Cure rate (CR) and egg reduction rate (ERR) with other soil-transmitted helminths (STH) and trematodes The CR will be calculated as the proportion of the STH or trematode positive participants at baseline who become egg-negative after treatment. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). In the week between 14 and 21 days post-treatment
See also
  Status Clinical Trial Phase
Completed NCT04999774 - Evaluation of Strongyloidiasis in Ecuador: a fieLd Laboratory Accuracy Study
Recruiting NCT05868005 - Delivering a Multi-disease Screening Tool to Migrant Populations N/A
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Terminated NCT03605758 - Treatment of Strongyloides Infection Phase 3
Completed NCT01570504 - Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis Phase 3
Completed NCT02105714 - Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders N/A
Not yet recruiting NCT04709848 - Strongyloides Stercoralis in Bone Marrow Transplant Recipients in the UK
Completed NCT00207753 - Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections N/A
Completed NCT00001245 - Study of Patients With Strongyloides Stercoralis Infection N/A